In the HT22 mouse hippocampal cell line and primary immature embryonic rat cortical neurons, glutamateinduced oxidative toxicity is associated with a delayed but chronic activation of extracellular signal-regulated kinase-1/2 (ERK-1/2). ERK-1/2 is also activated in HT22 cells that undergo caspase-dependent cell death upon inhibition of proteasome-dependent protein degradation brought about by MG132 treatment. As in glutamate-treated HT22 cells and primary neurons, inhibition of MEK-1, an upstream activator of ERK-1/2 protects against MG132-induced toxicity. Furthermore, activated ERK-1/2 is retained within the nucleus in glutamate-and MG132-treated HT22 cells. Although previous studies suggested that ERK-1/2 activation was downstream of many cell death-inducing signals in HT22 cells, we show here that cycloheximide, the Z-vad caspase inhibitor, and a nonlethal heat shock protect against glutamate-and MG132-induced toxicity without diminishing ERK-1/2 activation. In these cases, ERK-1/2, although chronically activated, is not retained within the nucleus but accumulates within the cytoplasm. Thus, persistent nuclear retention of activated ERK-1/2 may be a critical factor in eliciting proapoptotic effects in neuronal cells subjected to oxidative stress or proteasome inhibition.
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Mitogen-activated protein kinases (MAPKs)
1 are a family of serine-threonine protein kinases that are activated by a wide spectrum of stimuli and cellular stresses, ranging from mitogens and growth factors to neurotoxic factors (1) (2) (3) (4) (5) . MAPKs become catalytically active upon their dual phosphorylation at a specific threonine and tyrosine residue by MAPK kinases, which in turn are activated upon phosphorylation at specific serine residues by MAPK kinase kinases (6 -10) . The extracellular signal-regulated protein kinases ERK-1 and ERK-2 (ERK-1/2) are two closely related members of the MAPK family that are predominantly activated by growth factors (11) (12) (13) (14) (15) . ERK-1/2 has been found in many cases to be important for cell survival (10, 16) . Both isoforms are highly expressed in the brain, where they are activated not only by neurotrophins but also in response to a variety of signals (17) (18) (19) . A role for ERK-1/2 in learning and memory has been documented (20 -26) .
Activation of ERK-1/2 usually leads to its translocation from the cytoplasm to the nucleus, where it phosphorylates and regulates the activity of several transcription factors (27) (28) (29) . Nuclear localization of activated ERK-1/2 is usually transient (29, 30) and dependent on MEK-1/2, the upstream activator of ERK-1/2. The activation of ERK-1/2 and its concomitant dissociation from MEK-1 both require tyrosine phosphorylation by MEK-1/2 (31, 32) . Homodimerization of ERK-1/2 is crucial for its active translocation to the nucleus (33) , although there is a fraction of ERK-1/2 that enters the nucleus passively, as a monomer (32) .
Nuclear retention of MAPKs influences their regulation of specific transcription factor activity during cellular stress in yeast (34) . Furthermore, retention of active ERK-1/2 in the nucleus of ovarian cells determines the duration of specific phases of the cell cycle, even in response to chronic growth factor stimulation (35) . The accumulation of activated ERK-1/2 in the nucleus can also influence the cell cycle in PC12 cells (36) and survival of fibroblast cells (37) . Active ERK-1/2 is retained within the nucleus by nuclear anchoring proteins, which may be short-lived and require ongoing protein synthesis to accumulate to functional levels (37) . Nuclear export of ERK-1/2 requires its dephosphorylation by specific nuclear phosphatases (38) and binding of MEK1/2 (29, 32) . MEK-1 utilizes a potent nuclear export signal sequence to maintain its predominant cytoplasmic localization and return inactive ERK-1/2 to the cytoplasm for subsequent reutilization (29, 30, 35) .
In addition to their role in learning and memory, neuronal ERKs have been implicated in protection against neuronal cell death in vitro (10, 16) and in vivo (39, 40) . However, because additional models of neurotoxicity have been examined, contrasting effects of ERK-1/2 on cell survival have been observed. For example, the inhibition of ERK-1/2 protects neuronal cultures from cell death induced by seizure-like activity (4). Furthermore, oxidative toxicity in both immature cortical neurons and a neuronal cell line could be blocked upon inhibition of ERK-1/2 activation (41, 42) . In addition to in vitro studies supporting a role for ERK-1/2 activation in neurotoxicity, neuroprotective effects were associated with the inhibition of ERK-1/2 activation in an in vivo model of ischemia (43) . Because * The work was supported by National Institutes of Health Grant NS38319 (to D. B. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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ERK-1/2 can be activated, often in the same cell type, by both pro-survival factors such as brain-derived neurotrophic factor (14) and toxic stimuli (4, 44, 45) , ERK-1/2 activation alone may not be predictive of subsequent cellular survival responses.
In the HT22 mouse hippocampal cell line (46, 47) and primary cortical neurons, oxidative toxicity is associated with persistent activation of ERK-1/2 (41) . The inhibition of ERK-1/2 activation protects against glutamate-induced death in both HT22 cells and primary neurons, even if the inhibition is initiated hours after glutamate addition (41) . Given the contrasting reports of ERK-1/2 involvement in neuroprotection and neurotoxicity, we sought to uncover the mechanistic basis for the association of ERK-1/2 activation with oxidative toxicity in HT22 cells. Our results suggest that compartmentalization of activated ERK-1/2 plays a major role in its promotion of neuronal cell death. Thus, caspase-dependent cell death that results from oxidative toxicity in a cultured neuronal cell line and primary neurons is promoted when chronically activated ERK-1/2 is retained within the nucleus. However, chronic activation of ERK-1/2 brought about by glutamate-induced oxidative toxicity or by the inhibition of proteasome-dependent protein degradation can be tolerated in HT22 cells if active ERK-1/2 is excluded from nuclei.
EXPERIMENTAL PROCEDURES
Cell Line-The mouse HT22 hippocampal cell line is a subclone of the HT4 cell line (48, 49) that was selected for its sensitivity to glutamateinduced toxicity. The cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (Atlantic Biological, Norcross, GA).
Antibodies and Reagents-The anti-phospho-44/42 MAP kinase and anti-phospho-MEK-1 mouse monoclonal antibodies were obtained from New England Biolabs (Beverly, MA), the anti-MAP kinase 1/2 rabbit polyclonal antibody was from Upstate Biotechnology (Lake Placid, NY), the anti-lamin B antibody was from Santa Cruz Biotechnology (Santa Cruz, CA), and the anti-Hsp70 mouse monoclonal antibody was from StressGen Biotechnologies Corp. (Victoria, Canada). The phospho-ERK-specific peptide blocking was obtained from New England Biolabs. The fluorescein isothiocyanate-coupled anti-mouse IgG antibody was obtained from Roche Molecular Biochemicals, the Alexa 488 anti-mouse antibody was from Molecular Probes (Eugene, OR), and 4Ј,6-diamidino-2-phenylindole was from Sigma. Glutamate was dissolved in phosphate-buffered saline (PBS) to 1 M and immediately used at 5 mM. For heat shock experiments, HT22 cells were placed in a 41°C water bath for 60 min and then returned to 37°C in 5% CO 2 .
Cell Extracts and Immunoblotting-At different intervals after indicated treatments, HT22 cells were washed twice with ice-cold PBS containing 0.1 mM Na 3 VO 4 and collected on ice in 1 ml of PBS. The protein samples for blotting were prepared at 4°C by resuspension of cell pellet in lysis buffer containing 50 mM Tris-Cl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 1% Nonidet P-40, 5 mM NaF, 1 mM Na 3 VO 4 , 10 mM sodium pyrophosphate, 10 mM ␤-glycerolphosphate, 1 g/ml leupeptin, 1 g/ml pepstatin, 10 g/ml microcystein, and 5 g/ml aprotinin. Soluble extracts were prepared by centrifugation at 14,000 rpm for 10 min at 4°C. The protein concentrations in isolated extracts were determined using a Bradford protein assay kit from Bio-Rad with bovine serum albumin as standard. Equal amounts of total extract protein (5-10 g) were used for Western blot analysis (50) . Following transfer, Cell Viability-Cell viability was assessed at 37°C by measuring their ability to metabolize 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as described previously (51) . HT22 cells were grown overnight in a 96-well plate (see above) prior to any treatment. 15 h following indicated treatments, 10 l of MTT solution (5 mg/ml) was added to each well, and the cells were maintained in the same plate for 4 h at 37°C. 100 l of solubilization solution (50% dimethylformamide and 20% SDS, pH 4.8) was then added to each well. Following an overnight incubation, absorption at 570 nm was measured. The results were expressed relative to the control values specified in each experiment and were subjected to statistical analysis.
Statistical Analysis-All data were expressed as the means ϩ S.E. of four independent experiments. The significance of the difference among groups was determined using analysis of variance post-hoc comparison (Scheffe or Bonferonni-Dunn test).
RESULTS

Glutamate Treatment Leads to Persistent Nuclear Retention of Activated ERK-1/2-
The preferential accumulation of activated ERK-1/2 within the nucleus is one of the characteristic features of its activation by growth factors, mitogenic stimulation, and injury (5, 11, 31, 37, 40) . We had previously shown that glutamate-induced oxidative toxicity in the mouse HT22 hippocampal cell line is associated with the chronic activation of ERK-1/2 (41). Active ERK-1/2 contributes to toxicity in this paradigm, because HT22 cells can be protected from glutamate-induced cell death upon inhibition of ERK-1/2 activation (41). As shown in Fig. 1  (panel a) , the dually phosphorylated, active form of ERK-1/2 is localized mainly within the cytoplasm of untreated HT22 cells. However, active ERK-1/2 compartmentalization is changed upon chronic glutamate exposure because its accumulation within the nucleus is dramatically enhanced in HT22 cells treated with glutamate for 6 or 9 h (Fig. 1, panels b and c, and Fig. 2 ). Although we cannot definitively rule out the possibility that other ERK isoforms, e.g. ERK-1b (52), contribute to oxidative toxicity in HT22 cells, the major bands detected in our Western blot analyses are p44 and p42 ERK-1 and ERK-2, respectively (41) . Detection of the 46-kDa ERK-1b isoform in HT22 cell Western blots is variable and only visible upon prolonged exposure of the blots (data not shown). We therefore consider it likely that our IIF is predominantly visualizing ERK-1/2 localization.
Inclusion of a phospho-ERK-1/2-specific blocking peptide during the antibody binding reaction of IIF analysis completely eliminated nuclear staining of active ERK-1/2 in glutamatetreated HT22 cells (Fig. 1d) . The fact that some residual cytoplasm staining is visible in IIF analyses performed with the blocking peptide (Fig. 1d) suggests that the extent of active ERK-1/2 nuclear localization induced by glutamate treatment of HT22 cells may in fact be underestimated. Analysis of active ERK-1/2 nuclear localization by confocal microscopy in subsequent figures provides additional compelling evidence for induced nuclear transport of active ERK-1/2.
A number of control experiments were performed to examine the specificity of glutamate effects on nuclear transport or retention. Previously published ultrastructural analysis using electron microscopy revealed that glutamate treatment of HT22 cells does not lead to nuclear swelling or affect the integrity of the nuclear envelope (53) . We confirmed these results by IIF analyses with an anti-lamin B antibody (Fig. 1 , panels e and f), which revealed no obvious effect on nuclear envelope integrity upon glutamate treatment. Furthermore, glutamate treatment of HT22 cells did not affect the subcellular localization of active MEK-1 (Fig. 1, panels g and h) . Thus, the upstream activator of ERK-1/2 (i.e. MEK-1) remains cytoplasmic in response to glutamate treatment and is not efficiently retained within the nucleus.
Protective Effect of Cycloheximide in HT22 Cells Is Associated with Nuclear Exclusion of Activated ERK-1/2-Nuclear retention of MAPKs is regulated at various levels and is influenced by its phosphorylation state (5, 37, 54) , dual specificity protein phosphatases (38, 55, 56) , and specific phosphorylated nuclear targets of the MAPK (16, 17, 56) . The nuclear exclusion of ERK-1/2 in cycloheximide-treated fibroblasts (37) also indicates a role for unidentified short-lived nuclear proteins in MAPK nuclear retention. As shown in Fig. 3 , cycloheximide 
FIG. 7. Persistent activation of ERK by glutamate in HT22 cells
exposed to sublethal heat shock. HT22 cells were treated with 5 mM glutamate for 3, 6, 9, and 12 h and where indicated pre-exposed to a sublethal heat shock (41°C for 60 min) prior to glutamate treatment. The cells were then harvested and lysed, and active (A) or total (B) ERK in equivalent amounts of total lysate protein (20 g) was visualized by Western blot analysis using an active ERK-specific antibody (A) or a p42/44 ERK antibody (B). This blot is representative of results obtained in four independent experiments.
FIG. 8. Nuclear retention of active ERK is inhibited by prior
exposure of HT22 cells to heat shock. HT22 cells were either unstimulated (A), treated with 5 mM glutamate (B) for 6 h, or pre-exposed to a sublethal heat shock (41°C for 60 min) prior to a 6 h of glutamate treatment (C). The cells were fixed with 4% paraformaldehyde, incubated with an anti-phospho-ERK antibody overnight at ϩ4°C, and processed for IIF. The images were obtained from a confocal laser scanning microscope. protects HT22 cells from glutamate-induced toxicity, which is consistent with previously published studies (57) . Immature primary embryonic cortical neurons are also protected from glutamate-induced toxicity by cycloheximide (data not shown). Interestingly, activated ERK-1/2 levels remain high in cycloheximide-treated HT22 cells, even in the presence of glutamate (Fig. 4A) . Although chronically activated, ERK-1/2 was not retained in the nucleus of glutamate-treated HT22 cells exposed to cycloheximide (Fig. 5C and summarized in Fig. 2) . Thus, as first observed in a fibroblast cell line (37) , persistent retention of active ERK-1/2 within the nucleus appears to require some short-lived nuclear protein. Importantly, HT22 cells are resistant to glutamate-induced toxicity if activated ERK-1/2 is excluded from the nucleus.
A Sublethal Heat Shock That Protects HT22 Cells from Glutamate-induced Toxicity Blocks Persistent Nuclear Retention of Activated ERK-1/2-If the retention of active ERK-1/2 within
the nucleus contributes to glutamate-induced toxicity in HT22 cells, other neuroprotective treatments in this model might be expected to uniquely affect ERK-1/2 compartmentalization but not its activation. As shown in Fig. 6 , a sublethal heat shock (i.e. 60 min at 41°C) protects HT22 cells from glutamateinduced toxicity. Under these same conditions, glutamate-induced ERK-1/2 activation is not affected (Fig. 7) . However, the protective heat shock prevents persistent nuclear retention of activated ERK-1/2 in glutamate-treated HT22 cells (Fig. 8C) .
A Proteasome Inhibitor Induces Toxicity in HT22 Cells via an ERK-1/2-dependent Mechanism That Is Prevented upon Inhibition of Activated ERK-1/2 Nuclear
Retention-In previous studies using fibroblast cell lines, short-lived proteins were implicated in nuclear retention of ERK-1/2 given its persistent accumulation in cells treated with MG132, an inhibitor of the proteasome-mediated degradation machinery (58) . As shown in Fig. 9 , HT22 cells undergo cell death in response to MG132 treatment. MG132 has previously been shown to induce caspase-3-dependent apoptosis in mature embryonic cortical neurons (59) . As shown in Fig. 10 (A and B) , MG132 treatment of HT22 cells led to activation of ERK-1/2. Consistent with results obtained in fibroblasts, MG132 treatment of HT22 cells leads to persistent nuclear retention of active ERK-1/2 (Fig. 11,  A and B, and summarized in Fig. 2) . Interestingly, inhibition of ERK-1/2 activation by the MEK1/2 inhibitor U0126 (Fig. 10A ) was sufficient to rescue HT22 cells from MG132-induced toxicity (Fig. 9) . Cycloheximide, which is likewise protective against MG132-induced toxicity in HT22 cells (Fig. 9) , decreases MG132-induced ERK-1/2 activation (Fig. 10B ) and blocks the nuclear retention of active ERK-1/2 (Fig. 11, C and D, and summarized in Fig. 2) .
Inhibition of Caspase Activation in ERK-1/2-dependent Toxicity in HT22 Cells Is Associated with Reduced Nuclear
Retention of Active ERK-1/2-HT22 cells undergo a novel program of cell death that has features of both apoptosis and necrosis (46, 51, 53) . Caspase inhibition, which had previously been shown to block glutamate-induced toxicity in HT22 cells (Ref. 47 and Fig. 12A ) likewise blocks MG132-induced toxicity (Fig. 12B) . Glutamate-(data not shown) and MG132-induced (Fig. 13A ) ERK-1/2 activation in HT22 cells were not affected by Z-vad. However, as shown in Fig. 14C and summarized in Fig. 2 , active ERK-1/2 is not retained in the nucleus of HT22 cells treated with MG132 in the presence of Z-vad. Thus, even a relatively late event in a HT22 cell death program (i.e. caspase activation) can have an impact on ERK-1/2 nuclear retention and perhaps further enhance its proapoptotic functions.
DISCUSSION
In HT22 cells, caspase-dependent cell death induced by glutamate (41) or brought about by inhibition of proteasome function (this report) is associated with prolonged activation of ERK-1/2. Because inhibition of ERK-1/2 activation in both cases rescues HT22 cells from toxicity, ERK-1/2 must play a critical role in inducing cell death that has features of both apoptosis and necrosis (46, 47, 51) . In addition, we find that glutamate and MG132 treatment of HT22 cells leads to persistent nuclear retention of ERK-1/2. Because neuroprotective treatments (sublethal heat shock or caspase inhibition) that do not reduce ERK-1/2 activation were found uniformly to block nuclear retention of active ERK-1/2, we hypothesize that the persistent retention of active ERK-1/2 in the nucleus may be required for the proapoptotic properties of ERK-1/2 to be manifested. HT22 cells remain viable with chronically activated levels of ERK-1/2 if this kinase is excluded from the nucleus.
The compartmentalization of active ERK-1/2, even within an individual cell type can be differentially regulated and lead to diverse physiological responses (29, 60, 61 ). For example, tran- sient activation of ERK-1/2 during a proliferative response of PC12 cells to epidermal growth factor does not lead to ERK-1/2 translocation into nuclei (36) . In contrast, nerve growth factor treatment of PC12 cells, which triggers their differentiation, leads to a more sustained increase in activated ERK-1/2 that accumulates within nuclei (36) . Serum stimulation activates ERK-1/2 to the same extent in senescent and presenescent human diploid fibroblasts, but translocation of the activated ERK-1/2 into the nucleus of senescent cells is inefficient (62) . The forced accumulation of active ERK-1/2 into the nucleus of senescent cells, upon inhibition of MAPK phosphatase activity, allows them to overcome a block to cell cycle re-entry and DNA synthesis (62) . In fact, Brunet et al. (5) had previously established a requirement for nuclear accumulation of activated ERK-1/2 for fibroblast cell lines to re-enter the cell cycle upon growth factor stimulation following serum starvation.
What nuclear targets of ERK-1/2 could contribute to its proapoptotic effects in HT22 cells and cortical neurons? The cyclic AMP response element-binding protein (CREB) is a nuclear target of ERK-1/2 that is implicated in neuronal cell survival (63) . However, ERK-1/2 effects on CREB phosphorylation are indirect and mediated through the ERK-1/2 target kinase, Rsk (12) . Nonetheless, the indirect phosphorylation of CREB by activated ERK-1/2 is required for the late phase of long term potentiation (23) . CREB has been shown to promote neuronal cell survival (63) , making it unlikely to be associated with cell death induced by activated ERK-1/2 in HT22 cells. In fact, CREB phosphorylation does not appear to be altered by a toxic glutamate treatment of HT22 cells that activates ERK-1/2 and promotes its nuclear translocation (data not shown).
ERK-1/2 translocates into nuclei using both active and passive transport mechanisms (32) . Under basal conditions, activated ERK-1/2 is present in both the cytoplasm and nucleus of HT22 cells. Although growth factor-stimulated translocation of ERK-1/2 can be rapid (29, 30) , the transient increase in ERK-1/2 activation that occurs within minutes of glutamate treatment of HT22 cells was not associated with its quantitative nuclear transport (data not shown). The predominant accumulation of ERK-1/2 within the nucleus of HT22 cells occurs after 6 -9 h of glutamate treatment during a period in which intracellular reactive oxygen species and Ca 2ϩ levels are dramatically elevated (41, 47) .
Oxidative stress has been found to regulate the activity and expression of various protein phosphatases (64) . In fact, oxidative stress within human lymphocytes leads to an increased tyrosine phosphorylation and nuclear import of the STAT3 transcription factor, presumably via an inhibitory effect on a STAT3 phosphatase (65) . Because dephosphorylation of activated ERK-1/2 within the nucleus is required for its association with MEK-1 and subsequent nuclear export, inhibition of a nuclear ERK-1/2 phosphatase (i.e. MKP-1) (38) upon oxidative stress could be responsible for persistent accumulation of activated ERK-1/2 within the nucleus. MKP-1 levels do not appear to be altered by glutamate treatment of HT22 cells (preliminary results), but the effects of oxidative stress on MKP-1 activity must be assessed before its role in nuclear retention of ERK-1/2 can be excluded.
The various treatments that protect HT22 cells from glutamate-induced oxidative toxicity and MG132-induced cell death not only block the increased accumulation of activated ERK-1/2 within the nucleus of HT22 cells but also lead to a depletion of active ERK-1/2 from nuclei that exceeds that observed under basal conditions. The inefficient nuclear retention of active ERK-1/2 in cycloheximide-treated HT22 cells extends previous results obtained in fibroblast cells and reaffirm the hypothesis that nuclear retention of ERK-1/2 requires some rapidly turned over nuclear anchor (37) . The identity of such nuclear anchors for ERK-1/2 in mammalian cells remains unknown. In yeast nuclear retention of the MAPK, Hog1 is regulated both by its association with one of its nuclear target transcription factors (34) and a nuclear protein phosphatase (66) . Homologs of these yeast MAPK nuclear anchors could be responsible for nuclear retention of ERK-1/2 in oxidatively stressed neurons.
The mechanisms responsible for heat shock effects on ERK-1/2 nuclear retention have yet to be defined. Heat shock has most often been associated with the stimulation of protein import into nuclei (67, 68) , but recent experiments in yeast revealed a defect in nuclear retention of the Gsp1p GTPase upon heat shock (69) . Like its mammalian ortholog Ran, Gsp1p is an essential factor for nuclear protein import and export (69) . Once nuclear retention factors for ERK-1/2 in HT22 cells are identified, we would be able to assess the impact of heat shock on their compartmentalization or interaction with nuclear ERK-1/2.
The exclusion of active ERK-1/2 from the nucleus upon caspase inhibition suggests that active capases could contribute to nuclear retention of ERK-1/2 that is most apparent at late times following glutamate and MG132 treatment of HT22 cells. Interestingly, Ran is released from nuclei and redistributes to the cytoplasm in MCF-7 mammary carcinoma cells undergoing caspase-dependent cell death (70) . A disruption in Ran compartmentalization could affect nuclear protein import and/or export. Thus, once active ERK-1/2 begins to accumulate within nuclei and presumably trigger caspase activation, a positive feedback loop may be created in which ERK-1/2 nuclear export would be disrupted via direct effects of caspases on the nuclear transport machinery (i.e. Ran). Prolonged nuclear retention of active ERK-1/2 would ensue that could further accentuate the signals that lead to caspase activation.
What is the relationship between MG132-and glutamateinduced toxicity in HT22 cells and primary neurons? MG132 treatment of embryonic rat primary cortical neurons alters mitochondrial membrane potential leading to cytochrome c release and activation of caspase 3 (57) . In our experiments with analogous primary neurons, caspase-dependent cell death induced by MG132 could be blocked upon inhibition of ERK-1/2 activation. In contrast, MG132-induced apoptosis has been found to be associated in human lymphoid tumor cells with the activation of c-Jun NH 2 -terminal kinase/stress-activated protein kinase (71) but not ERK-1/2. Because inhibition of proteasomes can be either proapoptotic or protect against apoptosis, a more thorough examination of the signaling pathways activated upon proteasome inhibition will be required to reveal the basis for the differential effects of proteasome inhibition on cell survival. In summary, our findings highlight the importance of assessing the kinetic parameters and compartmentalization of MAPK activation when considering their impact on neuronal cell survival.
